Electronic health record data use in the assessment of quality indicators for glucocorticoid osteoporosis screening in systemic lupus erythematosus.
electronic health records
osteoporosis
quality indicators
systemic lupus erythematosus
Journal
Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
pubmed:
22
7
2022
medline:
20
10
2022
entrez:
21
7
2022
Statut:
ppublish
Résumé
To determine whether electronic health record (EHR) data components could be identified and used to assess bone health quality indicators in patients with systemic lupus erythematosus as a foundation for population health management. We identified patients in our EHR system who had diagnosis codes for lupus from 2012 to 2017 and characterized them based on the frequency and dosage of prescribed glucocorticoid medications. The medical records of patients who received repeated high-dose glucocorticoid orders were further reviewed for osteoporosis, osteoporotic fractures, receipt of appropriate preventive screening, and orders for protective medications based on established quality indicators. Descriptive statistics were calculated to summarize results. We identified 617 patients with a lupus diagnosis; 414 received glucocorticoid prescriptions, 189 received chronic, high-dose; and 83 received chronic, low-dose prescription orders. Of those with chronic high-dose glucocorticoid prescriptions, 14% had an osteoporosis diagnosis, 3% had an osteoporotic fracture, 51% received a prescription for calcium/vitamin D, 43% had bone mineral density screening orders, 20% received a spine radiograph order, 29% had a documented T-score, 12% received a prescription for osteoporosis medication, and 6% had a documented osteoporosis screening. We were able to identify data elements in the EHR for all nine components of the osteoporosis management quality indicator. It is possible to identify data in the EHR for all attributes of the quality indicator for osteoporosis in lupus patients who receive chronic high-dose glucocorticoids. However, missing data and need to extract data from text-based notes may make development of population management tools challenging.
Identifiants
pubmed: 35861184
doi: 10.1177/09612033221116726
pmc: PMC9588551
mid: NIHMS1823927
doi:
Substances chimiques
Glucocorticoids
0
Vitamin D
1406-16-2
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1516-1522Subventions
Organisme : NIAMS NIH HHS
ID : P30 AR072579
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR072263
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Références
Clin Rheumatol. 2017 Jan;36(1):97-102
pubmed: 27878408
Arthritis Care Res (Hoboken). 2020 Apr;72(4):461-488
pubmed: 32090466
Rheumatology (Oxford). 2014 Aug;53(8):1470-6
pubmed: 24681836
Semin Arthritis Rheum. 2010 Dec;40(3):193-200
pubmed: 20378155
Arthritis Care Res (Hoboken). 2010 Jul;62(7):993-1001
pubmed: 20589692
J Rheumatol. 2003 Sep;30(9):1955-9
pubmed: 12966597
Ann Rheum Dis. 2015 Sep;74(9):1706-13
pubmed: 24834926
J Am Pharm Assoc (2003). 2012 Jan-Feb;52(1):59-66
pubmed: 22257617
Arthritis Rheum. 2009 Mar 15;61(3):370-7
pubmed: 19248127
Lupus. 2020 Mar;29(3):263-272
pubmed: 31996109
Lupus Sci Med. 2015 Mar 11;2(1):e000066
pubmed: 25861455
Lupus. 2015 Feb;24(2):203-9
pubmed: 25267076
Rheumatology (Oxford). 2007 Jul;46(7):1185-90
pubmed: 17500075
Autoimmun Rev. 2011 May;10(7):383-8
pubmed: 21224016
Lupus Sci Med. 2016 Jan 19;3(1):e000098
pubmed: 26848397